Journal Article10.26355/eurrev_202307_32972
Effect of different doses of recombinant human growth hormone therapy on children with growth hormone deficiency: a retrospective observational study.
TL;DR: In this paper , the effects of different doses of recombinant human growth hormone (rhGH) treatment on children with growth hormone deficiency (GHD) were explored and compared between the two groups before and after one year of the treatment.
read more
Abstract: OBJECTIVE
The aim of this study was to explore the effects of different doses of recombinant human growth hormone (rhGH) treatment on children with growth hormone deficiency (GHD).
PATIENTS AND METHODS
Medical records of 174 GHD patients admitted to our hospital from June 2019 to January 2022 were retrospectively evaluated. A total of 136 patients met the inclusion criteria, of which 70 received 0.1 U/ (kg·d) (low-dose group) and 66 received 0.2 U/ (kg·d) dose of rhGH treatment (high-dose group). Growth and development status [height, weight, height standard deviation (HtSDS), growth rate], bone age, bone density, speed of sound (SOS) as distal radius bone mass, biochemical indicators of growth and development [insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3)], growth hormone (GH) levels and incidence of adverse reactions were collected and compared between the two groups before and after one year of the treatment.
RESULTS
After the treatment, height, weight, HtSDS, and growth rate of the two groups increased compared to before the treatment and were significantly higher in the high-dose group than in the low-dose group (p<0.05). After one year of treatment, the following observations were made: the bone age of the two groups increased compared to the baseline values and was higher in the high-dose group compared to the low-dose group (p<0.05). The SOS of the two groups decreased but was significantly higher in the high-dose group compared to the low-dose group (p<0.05). Serum levels of IGF-1, IGFBP-3, and GH in both groups increased compared to the baseline values and were higher in the high-dose group than in the low-dose group (p<0.05). There was no significant difference in the incidence of adverse reactions between the high-dose group (8.6%) and the low-dose group (6.1%) (p>0.05).
CONCLUSIONS
High-dose rhGH treatment for GHD is safe and can more effectively upregulate IGF-1, IGFBP-3, and GH, and promote the growth and development of children.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
References
Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.
Adda Grimberg,Sara A. DiVall,Constantin Polychronakos,David B. Allen,Laurie E. Cohen,Jose Bernardo Quintos,Wilma C. Rossi,Chris Feudtner,Mohammad Hassan Murad +8 more
TL;DR: This guideline provides recommendations for the clinical management of children and adolescents with growth failure from GHD, ISS, or PIGFD using the best available evidence.
The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders.
Werner F. Blum,Abdullah Alherbish,Afaf Alsagheir,Ahmed El Awwa,Walid Kaplan,Ekaterina Koledova,Martin O. Savage +6 more
TL;DR: Understanding and use of measurements of the components of the IGF system are less current in clinical practice, but IGF-I monitoring during GH therapy also informs the clinician about adherence and provides a safety reference to avoid over-dosing during long-term management.
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
Cheri Deal,Joel Steelman,Elpis Vlachopapadopoulou,Renata Stawerska,Lawrence Silverman,Moshe Phillip,Ho-Seong Kim,Cheol Woo Ko,Oleg Malievskiy,José F. Cara,Carl L. Roland,Carrie T. Taylor,Srinivas Rao Valluri,Michael Wajnrajch,Aleksandra Pastrak,Bradley S. Miller +15 more
TL;DR: The efficacy of once-weekly somatrogon was noninferior to once-daily somatropin, with similar safety and tolerability profiles, in prepubertal children with GHD.
Effect of recombinant human growth hormone therapy on blood lipid and carotid intima-media thickness in children with growth hormone deficiency
TL;DR: The RhGH replacement therapy in GHD children can improve both the blood lipid profile and carotid intima-media thickness, with higher-dose rhGH therapy showing superior effects.
Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
TL;DR: The 10-year data suggest that biosimilar rhGH is well tolerated across pediatric and adult indications, and need to be confirmed in larger cohorts, highlighting the importance of long-term post-marketing studies.